Late-stage cancer/autoimmune biotech developing in-licensed antibodies in China.
Industry: Health Care
First Day Return: -10.7%
Industry: Health Care
IPO Data | |
---|---|
IPO File Date | 10/29/2019 |
Offer Price | $14.00 |
Price Range $12.00 - $15.00 | |
Offer Shares (mm) | 7.4 |
Deal Size ($mm) | $104 |
Lock-Up Date | IPO Pro Only |
Street Research | IPO Pro Only |
IPO Data | |
---|---|
IPO Date | 01/16/2020 |
Offer Price | IPO Intelligence Only |
Price Range | IPO Intelligence Only |
Offer Shares (mm) | IPO Intelligence Only |
Deal Size ($mm) | $104 |
Lock-Up Date | IPO Intelligence Only |
Street Research | IPO Intelligence Only |
Underwriters |
---|
IPO Intelligence Only |
Company Data | |
---|---|
Headquarters | Shanghai, China |
Founded | 2014 |
Employees at IPO | 185 |
Website www.i-mabbiopharma.com/en/ |